UK medicines regulation disincentivising investment in research development, finds survey The majority of pharmaceutical manufacturers responding to a survey have said the UK’s medicines regulatory environment has an ‘unfavourable’ impact on their decision to invest in research development...

An #ABPI survey has revealed that 56% of pharmaceutical manufacturers said the UK's regulatory environment was 'somewhat unfavourable', while 22% said it was 'very unfavourable'

#regulationinpharma #ukpharma #MHRA

pharmaceutical-journal.com/article/news...